Home > Healthcare > Medical Devices > Diagnostic Devices > D-dimer Testing Market

D-dimer Testing Market Trends

Report ID: GMI5972
Published Date: Jun 2023
Report Format: PDF

Download Free Sample

D-dimer Testing Market Trends

Technological advancements regarding D-dimer testing are anticipated to stimulate market progression. Immunoassay techniques, such as enzyme-linked immunosorbent assay (ELISA), have been widely used in D-dimer testing. Advances in immunoassay technology have led to the development of overly sensitive and specific assays for detecting D-dimer levels in blood samples. Moreover, integration of D-dimer testing with digital platforms and electronic medical records has facilitated seamless data management, result interpretation, and communication between healthcare professionals. This digitization improves workflow efficiency and enables remote monitoring and consultation.

Authors: Mariam Faizullabhoy

Frequently Asked Questions (FAQ) :

The global market for d-dimer testing was over USD 1 billion in 2022 and will reach more than USD 2 billion by 2032.

The enzyme-linked immunosorbent assay (ELISA) segment will record more than USD 700 million by 2032 as they are highly sensitive and capable of detecting even low levels of D-dimer in blood samples.

The U.S. d-dimer testing industry accounted for more than USD 450 billion in 2022 and will grow to USD 615 billion by 2032 owing to the affordability of d-dimer testing among the target population base and ongoing technological developments.

Abbott Laboratories, BioMedica Diagnostics, biomérieux SA, Diazyme Laboratories Inc. (General Atomics), F. Hoffmann-La Roche Ltd., HORIBA Ltd., Quidel Corporation, Sekisui Diagnostics LLC (Sekisui Chemical Co. Ltd.), Siemens Healthcare GmbH, and Thermo Fisher Scientific Inc.